Showing results (31-40 of 46) with videos related to

Sort By:
Pageof 5
Scientific Reports|November 8, 2023
Efficacy of second-line chemotherapy after treatment with gemcitabine plus nab-paclitaxel or FOLFIRINOX in patients with metastatic pancreatic cancerMasaru Fukahori, Yoshinobu Okabe, Mototsugu Shimokawa, et al.
Scientific Reports|May 31, 2023
C-reactive protein/albumin ratio is the most significant inflammatory marker in unresectable pancreatic cancer treated with FOLFIRINOX or gemcitabine plus nab-paclitaxelTsuyoshi Shirakawa, Akitaka Makiyama, Mototsugu Shimokawa, et al.
Oncology|October 4, 2022
Multicenter Retrospective Analysis of Original versus Modified FOLFIRINOX in Metastatic Pancreatic Cancer: Results of the NAPOLEON StudyJunichi Nakazawa, Nobuhiro Tsuruta, Mototsugu Shimokawa, et al.
Journal of Geriatric Oncology|July 3, 2021
Gemcitabine plus nab-paclitaxel in older patients with metastatic pancreatic cancer: A post-hoc analysis of the real-world data of a multicenter study (the NAPOLEON study)Futa Koga, Yasunori Kawaguchi, Mototsugu Shimokawa, et al.
Therapeutic Advances in Medical Oncology|April 29, 2026
Predictors of prolonged progression-free survival in patients with unresectable or recurrent pancreatic cancer treated with nanoliposomal irinotecan with fluorouracil and folinic acid (NAPOLEON-2 study)Yasunori Kawaguchi, Kohei Hayashi, Mototsugu Shimokawa, et al.
Therapeutic Advances in Medical Oncology|February 24, 2025
Comparison of inflammatory markers before and after nanoliposomal irinotecan and fluorouracil with folic acid in patients with pancreatic cancer: results from the NAPOLEON-2 study (NN-2302)Tomonori Araki, Kohei Hayashi, Mototsugu Shimokawa, et al.
BMC Cancer|May 27, 2026
Effect of biliary drainage and biliary tract infection in unresectable pancreatic cancer treated with nanoliposomal irinotecan with fluorouracil and folinic acid: a multicenter, prospective cohort study (NAPOLEON-2)Wataru Yoshioka, Tsuyoshi Shirakawa, Mototsugu Shimokawa, et al.
Asia-Pacific Journal of Clinical Oncology|November 4, 2025
Nanoliposomal Irinotecan With Fluorouracil and Folinic Acid in Older Versus Younger Patients With Unresectable Pancreatic Cancer: The Multicenter NAPOLEON-2 StudyAtsuko Kakihara, Shigeyuki Takeshita, Mototsugu Shimokawa, et al.
BMC Cancer|October 22, 2025
Impact of biliary drainage for unresectable pancreatic cancer treated with nanoliposomal irinotecan with fluorouracil and folinic acid: retrospective results from the NAPOLEON-2 studyKazuo Nishikawa, Taiga Otsuka, Mototsugu Shimokawa, et al.
Frontiers in Oncology|August 1, 2025
Efficacy of third-line chemotherapy following nanoliposomal irinotecan combined with fluorouracil and folinic acid as second-line treatment for unresectable pancreatic cancerKeisuke Miwa, Reina Kawasaki, Mototsugu Shimokawa, et al.
Pageof 5